Neofollin (Estradiol Valerate)

Estradiol valerate, the active ingredient in Neofollin, is an estrogen presented as an injectable solution for intramuscular use. It treats menopausal hormone therapy, hypoestrogenism and primary ovarian insufficiency in women.

GNH USA supplies Neofollin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neofollin (estradiol valerate) is used in estrogen‑dependent conditions to restore hormonal balance.

- Menopausal hormone therapy: alleviates vasomotor symptoms and helps maintain bone density in post‑menopausal women. - Hypoestrogenism: restores physiologic estrogen levels in women with deficient endogenous production. - Primary ovarian insufficiency: provides estrogen replacement to support secondary sexual characteristics and bone health.

Neofollin may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea or vomiting - Breast tenderness or enlargement - Headache or dizziness - Local injection site pain or erythema - Fluid retention or mild edema

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Stroke or myocardial infarction - Endometrial hyperplasia or carcinoma - Hepatic dysfunction or cholestasis

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Cardiovascular risk assessment: review history of thromboembolic disease. - Liver function monitoring: estradiol can affect hepatic metabolism. - Contraindication in estrogen‑dependent tumors: avoid use in known breast or endometrial cancer. - Bone health evaluation: consider baseline density and follow‑up. - Pregnancy and lactation: use only if clearly indicated after risk‑benefit analysis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Estradiol valerate can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of thrombotic events. - Selective estrogen receptor modulators (e.g., tamoxifen): antagonistic effects. - Aromatase inhibitors: counteract estrogenic activity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Thyroid hormone replacement: may require dose adjustment of levothyroxine.